At the news
? BULLISHIMPACT 7/10 8-K filed May 12, 2026 at 16:05 ET
Immunome reported Q1 2026 results: net loss of $53.8M ($-0.48/share) vs consensus $-0.60, a beat of 20% on EPS. The NDA submission for varegacestat in desmoid tumors is the key catalyst, with ASCO oral presentation and EU MAA planned. Cash runway into 2028 supports pipeline execution.
- NDA submitted to FDA for varegacestat in desmoid tumors (April 2026)
- Phase 3 RINGSIDE data selected for oral presentation at ASCO 2026
- Q1 2026 net loss $53.8M ($-0.48/share) vs consensus $-0.60, 20% beat
- Cash and equivalents $582.7M, runway into 2028
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access